)
)
DiaMedica Therapeutics Investor Relations Material
Latest events
Q4 2024
DiaMedica Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from DiaMedica Therapeutics Inc
Access all reports
DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious diseases, with an emphasis on acute ischemic stroke (AIS) and cardio-renal diseases. The company is dedicated to improving patient outcomes by advancing its lead product candidate, DM199, which is a synthetic version of the human tissue kallikrein-1 (KLK1) protein. The company is headquartered in Minneapolis, Minnesota, and its shares are listed on the Nasdaq.
Key slides for DiaMedica Therapeutics Inc
Corporate Presentation
DiaMedica Therapeutics Inc
Corporate Presentation
DiaMedica Therapeutics Inc
Latest articles
)
Adobe: Equipping the Architects of Digital Expression
The story of how Adobe grew from a small garage upstart to one of the largest and most dominant software companies in the world.
21 Mar 2025
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
Ticker symbol
DMAC
Country
🇺🇸 United States